Cancer Blood Markers: Clinical Applications
The most clinically useful tumor-associated blood markers are CEA for colorectal cancer monitoring, CA 15-3/CA 27.29 for metastatic breast cancer monitoring, CA 125 for ovarian cancer therapy monitoring, PSA for prostate cancer, AFP and HCG for germ cell tumors, and CA 19-9 for pancreatic cancer monitoring—though none are recommended for cancer screening in asymptomatic populations. 1, 2
Key Principle: Tumor Markers Are NOT Screening Tools
A critical caveat: tumor markers should not be used for cancer screening in the general population due to insufficient sensitivity and specificity. They lack the ability to detect early-stage disease reliably and produce too many false positives in benign conditions 3, 1, 2.
Colorectal Cancer: CEA (Carcinoembryonic Antigen)
CEA is the marker of choice for colorectal cancer management, with specific evidence-based applications 1:
Appropriate Uses:
- Preoperative staging: May be ordered if results would influence surgical planning (though elevated levels >5 ng/mL don't justify adjuvant therapy decisions alone)
- Postoperative surveillance: Measure every 2-3 months for at least 3 years in stage II-III patients who are surgical candidates. Wait until chemotherapy is completed before initiating surveillance, as chemotherapy can falsely elevate CEA 1
- Monitoring metastatic disease: Measure at treatment initiation, then every 1-3 months during active therapy. Two consecutive values above baseline indicate progressive disease, even without radiographic confirmation 1
Critical Pitfall:
Spurious CEA rises can occur during the first 4-6 weeks of new therapy, especially with oxaliplatin—exercise caution in interpretation during this window 1.
Breast Cancer Markers
CA 15-3 and CA 27.29
These markers are NOT recommended for screening, diagnosis, staging, or routine surveillance after primary treatment 3. The evidence shows:
- Sensitivity increases with stage (5-30% stage I, 65-90% stage IV), but low levels don't exclude metastases 3
- CA 27.29 may detect recurrence 5.3 months earlier than clinical symptoms (sensitivity 57.7%, specificity 98%), but this early detection has not demonstrated improved survival, quality of life, or cost-effectiveness 3
- The FDA approved CA 27.29, but FDA approval doesn't require demonstration of clinical benefit 3
Limited acceptable use: In metastatic disease without readily measurable lesions, rising CA 15-3/CA 27.29 may suggest treatment failure 3.
CEA in Breast Cancer
CEA is not recommended for breast cancer screening, diagnosis, staging, or routine surveillance 3. Only acceptable use: In metastatic disease without measurable lesions or elevated MUC-1 markers, rising CEA may suggest treatment failure 3.
Estrogen and Progesterone Receptors
These should be measured on every primary breast cancer and may be measured on metastatic lesions if results would influence treatment planning. They identify patients most likely to benefit from endocrine therapy in both pre- and postmenopausal patients 3.
Pancreatic Cancer: CA 19-9
CA 19-9 has limited clinical utility in pancreatic cancer 1:
- Not recommended for screening or determining operability
- Cannot provide definitive evidence of recurrence without imaging confirmation
- May be measured at treatment initiation and every 1-3 months during therapy for locally advanced/metastatic disease
- Rising serial values may indicate progression but require confirmation with other studies 1
Germ Cell Tumors: AFP and HCG
AFP and HCG are the most clinically useful tumor markers, approaching the ideal 2, 4. For non-seminomatous germ cell tumors:
- Useful for diagnosis, staging, and prognosis
- Levels correlate with disease stage
- Rising levels after therapy almost always indicate recurrence
- HCG in gestational trophoblastic tumors is the marker closest to ideal: confirms diagnosis, stage, treatment response, and predicts relapse 4
Ovarian Cancer: CA 125
CA 125 is valuable for monitoring therapy in patients with established ovarian cancer 2, though not recommended for screening in the general population.
Prostate Cancer: PSA
PSA is widely used but its value in screening for reducing prostate cancer mortality remains unclear 2. This represents an ongoing controversy in the field.
Markers NOT Recommended for Routine Clinical Use
The following have insufficient evidence for clinical application 3, 1:
- Colorectal cancer: CA 19-9, LASA, DNA ploidy, p53, ras, TS, DPD, TP, MSI, 18q/DCC
- Breast cancer: Cathepsin-D, angiogenesis markers
Emerging Technologies
While not yet ready for routine clinical use, newer approaches show promise 5, 6:
- Circulating tumor cells (CTCs)
- Circulating tumor DNA (ctDNA)
- Extracellular vesicles
- Cell-free RNA
- AI-assisted interpretation of complex biomarker panels
The fundamental limitation: Most tumor markers lack tumor specificity and can be elevated in benign conditions, making interpretation challenging and requiring correlation with clinical context 7.